Emerging drugs for the treatment of cervical cancer

Serrano-Olvera, Alberto; Cetina, Lucely; Coronel, Jaime; Dueñas‐González, Alfonso

doi:10.1517/14728214.2015.1002768

Cited by 25 publications

(17 citation statements)

References 110 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cervical cancer, especially metastatic cervical cancer with a high invasive potential and innite proliferation, [1][2][3][4] is the most common primary malignant tumour in women worldwide. [5][6][7][8][9][10][11] The worldwide incidence rate of cervical cancer has been on the rise in recent years, and its metastasis remains one of the main pathological conditions endangering human life worldwide.…”

Section: Introductionmentioning

confidence: 99%

Microwave-assisted synthesis of polypyridyl ruthenium(ii) complexes as potential tumor-targeting inhibitors against the migration and invasion of Hela cells through G2/M phase arrest

Cao

Zheng

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Microwave-assisted synthesis of polypyridyl ruthenium(ii) complexes as potential tumor-targeting inhibitors against the migration and invasion of Hela cells through G2/M phase arrest

Cao

Zheng

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…6,7 On 7 February 2013, the National Cancer Institute issued a Press Release indicating that incorporation of the anti-VEGF monoclonal antibody, bevacizumab, with two chemotherapy doublets significantly improved overall survival (OS) at the second interim analysis of the phase III randomized clinical trial, Gynecologic Oncology Group (GOG) protocol 240. 8 Within one month of formal publication of these interim results, on 10 March 2014 the United Kingdom’s Cancer Drug Fund approved bevacizumab in combination with chemotherapy for women in England with recurrent/metastatic cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

et al. 2017

View full text Add to dashboard Cite

Background On August 14, 2014, the United States Food and Drug Administration approved the anti-angiogenesis drug, bevacizumab, for women with advanced cervical cancer based on a 2012 interim analysis of 271 deaths on GOG protocol 240. We now report the planned protocol-specified final analysis of the primary objective, overall survival (OS). Methods A phase III randomized trial using a 2×2 factorial design was conducted to determine whether intravenous chemotherapy [(cisplatin 50 mg/m2 plus paclitaxel 135 or 175 mg/m2) or (topotecan 0.75 mg/m2 days 1–3 plus paclitaxel 175 mg/m2)] with or without bevacizumab (15 mg/kg) improves OS in recurrent/persistent/metastatic cervical cancer. Patients were prospectively stratified by performance status, prior radiosensitizing platinum, and disease status. We estimated enrolling 450 patients with 346 deaths at final analysis to provide 90% power to detect a 30% reduction in risk of death. Findings On March 7, 2014, 348 deaths occurred among 452 patients. Regimens administering bevacizumab continued to demonstrate significant improvement in OS: 16.8 vs 13.3 mos (HR 0.77;95% CI 0.62–0.95;p=0.0068). Updated progression-free survival also favored bevacizumab (HR 0.68;95% CI 0.56–0.84;p=0.0002). Final OS among 20% (n=91) not treated with prior pelvic radiotherapy was 24.5 (bevacizumab) vs 16.8 mos (without bevacizumab). Fistula (any grade) occurred in 14.5% (n=32) receiving bevacizumab (all previously irradiated). Grade 3+ fistula developed in 5.9% (n=13) and did not result in surgical emergency, sepsis and/or death. Post-progression OS was not significantly different among those who did and did not receive bevacizumab (median 8.4 vs 7.1 mos: HR 0.32;95% CI 0.66–1.05;p=0.06). Interpretation The benefit conferred by incorporation of bevacizumab is sustained with extended follow-up as evidenced by the survival curves remaining separated. Following progression on bevacizumab, a negative rebound effect was not observed. This represents proof-of-concept of the efficacy and tolerability of anti-angiogenesis therapy in advanced cervical cancer. Funding National Cancer Institute (USA).

show abstract

“…Palliation with platinum-based chemotherapy remains the standard of care for inoperable patients who have advanced disease (63). Few advances in medical management have occurred in recent years in the treatment of advanced recurrent gynecological malignancies, and a poor prognosis remains (12).…”

Section: Discussionmentioning

confidence: 99%

Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review

et al. 2016

View full text Add to dashboard Cite

Abstract. The aim of the present systematic review was to analyze the potential impact of mammalian target of rapamycin (mTOR) inhibitors on the treatment of cervical squamous cell carcinoma (CSCC). A systematic literature search was conducted in PubMed, PMC, Scopus, Cochrane Library, LILACS, Web of Science, Google Scholar and ScienceDirect on January 19, 2015, without time and language restrictions. Studies that evaluated women of any age with CSCC and who received mTOR inhibitors alone or in association with other treatments were considered. Randomized and non-randomized clinical trials were included, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was followed. Selected studies were methodologically appraised according to the Grades of Recommendation, Assessment, Development and Evaluation method to assess the quality of evidence. Of 642 identified citations, 43 studies were fully reviewed; however, only 3 studies met the inclusion criteria and were used for qualitative analysis. Of these, two studies were phase 1 and one was a phase 2 clinical trial. The studies included were not conclusive with regard to the association between mTOR inhibitor treatment and cervical cancer. The main analysis of secondary endpoints revealed that individuals treated with other drugs in association with mTOR inhibitors achieved partial responses (15.4-33.3%) or stable disease (17.6-28%). Treatment with mTOR inhibitors in general was well tolerated in patients with metastatic disease. The predominant toxicities were grade 1 and 2. The phase 1 trials included in this review demonstrated that mTOR inhibitor treatments are feasible and safe. However, the currently available evidence is insufficient to determine the effect of mTOR inhibitors on CSCC, and further investigation in high-quality, randomized clinical trials is required.

show abstract

Emerging drugs for the treatment of cervical cancer

Cited by 25 publications

References 110 publications

Microwave-assisted synthesis of polypyridyl ruthenium(ii) complexes as potential tumor-targeting inhibitors against the migration and invasion of Hela cells through G2/M phase arrest

Microwave-assisted synthesis of polypyridyl ruthenium(ii) complexes as potential tumor-targeting inhibitors against the migration and invasion of Hela cells through G2/M phase arrest

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review

Contact Info

Product

Resources

About